story of the week
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
J. Clin. Oncol 2020 May 29;[EPub Ahead of Print], NU Lin, V Borges, C Anders, RK Murthy, E Paplomata, E Hamilton, S Hurvitz, S Loi, A Okines, V Abramson, PL Bedard, M Oliveira, V Mueller, A Zelnak, MP DiGiovanna, T Bachelot, AJ Chien, R O'Regan, A Wardley, A Conlin, D Cameron, L Carey, G Curigliano, K Gelmon, S Loibl, J Mayor, S McGoldrick, X An, EP WinerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.